

## Food and Drug Administration, HHS

## § 17.1

the hearing specified in §16.80(a) together with all other relevant information and views available to FDA in determining whether regulatory action should be taken and, if so, in what form.

(b) With respect to a regulatory hearing required by the act or a regulation under §16.1(b)—

(1) The administrative record of the hearing specified in §16.80(a) constitutes the exclusive record for decision;

(2) On the basis of the administrative record of the hearing, the Commissioner shall issue a written decision stating the reasons for the Commissioner's administrative action and the basis in the record; and

(3) For purposes of judicial review under §10.45, the record of the administrative proceeding consists of the record of the hearing and the Commissioner's decision.

### Subpart F—Reconsideration and Stay

#### § 16.119 Reconsideration and stay of action.

After any final administrative action that is the subject of a hearing under this part, any party may petition the Commissioner for reconsideration of any part or all of the decision or action under §10.33 or may petition for a stay of the decision or action under §10.35.

[44 FR 22367, Apr. 13, 1979, as amended at 54 FR 9037, Mar. 3, 1989]

### Subpart G—Judicial Review

#### § 16.120 Judicial review.

Section 10.45 governs the availability of judicial review concerning any regulatory action which is the subject of a hearing under this part

## PART 17—CIVIL MONEY PENALTIES HEARINGS

Sec.

- 17.1 Scope.
- 17.2 Maximum penalty amounts.
- 17.3 Definitions.
- 17.5 Complaint.
- 17.7 Service of complaint.
- 17.9 Answer.
- 17.11 Default upon failure to file an answer.

- 17.13 Notice of hearing.
- 17.15 Parties to the hearing.
- 17.17 Summary decisions.
- 17.18 Interlocutory appeal from ruling of presiding officer.
- 17.19 Authority of the presiding officer.
- 17.20 Ex parte contacts.
- 17.21 Prehearing conferences.
- 17.23 Discovery.
- 17.25 Exchange of witness lists, witness statements, and exhibits.
- 17.27 Hearing subpoenas.
- 17.28 Protective order.
- 17.29 Fees.
- 17.30 Computation of time.
- 17.31 Form, filing, and service of papers.
- 17.32 Motions.
- 17.33 The hearing and burden of proof.
- 17.34 Determining the amount of penalties and assessments.
- 17.35 Sanctions.
- 17.37 Witnesses.
- 17.39 Evidence.
- 17.41 The administrative record.
- 17.43 Posthearing briefs.
- 17.45 Initial decision.
- 17.47 Appeals.
- 17.48 Harmless error.
- 17.51 Judicial review.
- 17.54 Deposit in the Treasury of the United States.

AUTHORITY: 21 U.S.C. 331, 333, 337, 351, 352, 355, 360, 360c, 360f, 360i, 360j, 371; 42 U.S.C. 262, 263b, 300aa-28; 5 U.S.C. 554, 555, 556, 557.

SOURCE: 60 FR 38626, July 27, 1995, unless otherwise noted.

EDITORIAL NOTE: Nomenclature changes to part 17 appear at 68 FR 24879, May 9, 2003.

#### § 17.1 Scope.

This part sets forth practices and procedures for hearings concerning the administrative imposition of civil money penalties by FDA. Listed below are the statutory provisions that authorize civil money penalties that are governed by these procedures.

(a) Section 303(b)(2) and (b)(3) of the Federal Food, Drug, and Cosmetic Act (the act) authorizing civil money penalties for certain violations of the act that relate to prescription drug marketing practices.

(b) Section 303(f)(1) of the act authorizing civil money penalties for certain violations of the act that relate to medical devices and section 303(f)(2) of the act authorizing civil money penalties for certain violations of the act that relate to pesticide residues.

**§ 17.2**

**21 CFR Ch. I (4–1–07 Edition)**

(c) Section 307 of the act authorizing civil money penalties for certain actions in connection with an abbreviated new drug application or certain actions in connection with a person or individual debarred under section 306 of the act.

(d) Section 539(b)(1) of the act authorizing civil money penalties for certain violations of the act that relate to electronic products.

(e) Section 351(d)(2) of the Public Health Service Act (the PHS Act) authorizing civil money penalties for violations of biologic recall orders.

(f) Section 354(h)(3) of the PHS Act, as amended by the Mammography

Quality Standards Act of 1992 and the Mammography Quality Standards Act of 1998, authorizing civil money penalties for failure to obtain a certificate and failure to comply with established standards, among other things.

(g) Section 2128(b)(1) of the PHS Act authorizing civil money penalties for intentionally destroying, altering, falsifying, or concealing any record or report required to be prepared, maintained, or submitted by vaccine manufacturers under section 2128 of the PHS Act.

[60 FR 38626, July 27, 1995, as amended at 69 FR 43301, July 20, 2004]

**§ 17.2 Maximum penalty amounts.**

The following table shows maximum civil monetary penalties associated with the statutory provisions authorizing civil monetary penalties under the act or the Public Service Act.

**CIVIL MONETARY PENALTIES AUTHORITIES ADMINISTERED BY FDA AND ADJUSTED MAXIMUM PENALTY AMOUNTS**

U.S.C. Section	Description of Violation	Former Maximum Penalty Amount (in dollars)	Assessment Method	Date of Last Penalty	Adjusted Maximum Penalty Amount (in dollars)
(a) 21 U.S.C.					
(1) 333(b)(2)(A)	Violation of certain requirements of the Prescription Drug Marketing Act (PDMA)	50,000	For each of the first two violations in any 10-year period	2004	55,000
(2) 333(b)(2)(B)	Violation of certain requirements of the PDMA	1,000,000	For each violation after the second conviction in any 10-year period	2004	1,100,000
(3) 333(b)(3)	Violation of certain requirements of the PDMA	100,000	Per violation	2004	110,000
(4) 333(f)(1)(A)	Violation of certain requirements of the Safe Medical Devices Act (SMDA)	15,000	Per violation	2004	16,500
(5) 333(f)(1)(A)	Violation of certain requirements of the SMDA	1,000,000	For the aggregate of violations	2004	1,100,000
(6) 333(f)(2)(A)	Violation of certain requirements of the Food Quality Protection Act of 1996 (FQPA)	50,000	Per individual	2004	55,000
(7) 333(f)(2)(A)	Violation of certain requirements of the FQPA	250,000	Per "any other person"	2004	275,000